Ground Hog Day For Merck: FDA Again Cancels Sugammadex Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is conducting additional inspections of the site of a hypersensitivity study the agency requested in 2008; concerns about the study derailed a committee review in 2013.
You may also be interested in...
Keeping Track: Submissions Galore, And Still More 'Breakthroughs'
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Kybella, Ixinity, Raplixa Approved; Three 'Complete Responses' Surprise No One
The latest drug development news and highlights from our FDA Performance Tracker.
Sugammadex Clinical Trial Issues Still Causing Trouble For Merck
After FDA abruptly cancelled an advisory committee meeting on the anesthesia injection product in July to review trial site inspection results for a hypersensitivity study, it issues a “complete response” letter indicating site “operational” concerns.